INmune Bio corrects CEO/CFO base salaries and CEO option grant in employment agreements

Inmune Bio, Inc.

CEO David Moss base salary corrected to $454,000 per annum; option grant corrected to 750,000 shares.
CFO Cory Ellspermann base salary corrected to $240,000 per annum.
Amendments effective retroactively to November 26, 2025, to fix clerical errors in original agreements.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.